Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency-Reference-Cited by-同舟云学术

Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency

Published:2019-07 Issue:7 Volume:25 Page:1355-1362
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Dvorak Christopher C.^ORCID,Long-Boyle Janel,Dara Jasmeen,Melton Alexis,Shimano Kristin A.,Huang James N.,Puck Jennifer M.,Dorsey Morna J.,Facchino Janelle,Chang Catherine K.,Cowan Morton J.^ORCID

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference32 articles.

1. B-cell reconstitution for SCID: Should a conditioning regimen be used in SCID treatment?;Haddad;J Allergy Clin Immunol,2013

2. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency;Dvorak;J Allergy Clin Immunol,2014

3. Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID;Dvorak;Bone Marrow Transplant,2017

4. Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study;Heimall;Blood,2017

5. SCID genotype and 6-month post-transplant CD4 count predict survival and immune recovery: a PIDTC retrospective study;Haddad;Blood,2018

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia;Transplantation and Cellular Therapy;2024-09

3. In vivo hematopoietic stem cell modification by mRNA delivery;Science;2023-07-28

4. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium;The Lancet;2023-07

5. Homology-Directed-Repair-Based Genome Editing in HSPCs for the Treatment of Inborn Errors of Immunity and Blood Disorders;Pharmaceutics;2023-04-24